Anthropic acquired biotech AI startup Coefficient Bio in a deal valued at approximately $400 million in stock, according to people familiar with the matter. Sources confirmed the transaction, although detailed financial terms were not publicly disclosed.
Deepening Forays Into Healthcare And Life Sciences
The acquisition follows Anthropic’s earlier launch of Claude for Life Sciences, a tool designed to support scientific research and drug discovery. The deal expands the company’s activity in healthcare and biotechnology. Anthropic is increasing its focus on applying AI models to scientific workflows, including data analysis and experimental design. Expansion into life sciences reflects broader industry trends.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Transforming Computational Drug Discovery
Coefficient Bio was founded eight months ago by Samuel Stanton and Nathan C. Frey, both former researchers at Genentech’s Prescient Design group. The company focused on applying AI to drug discovery and biological research processes. Its technology aims to improve efficiency in identifying drug candidates and analyzing biological data. Early-stage development reflects growing interest in AI-driven research tools.
Strategic Talent And Expertise Integration
Around 10 employees from Coefficient Bio will join Anthropic following the acquisition, strengthening its health and life sciences team. The group will contribute to the development of AI models for scientific and medical applications. Access to specialized talent supports the expansion of capabilities in drug discovery and biological research.
Industry Context And Outlook
Investment in AI for drug discovery has increased as companies seek to reduce development timelines and costs. Large technology firms and startups are expanding activity in this area. Further developments will depend on how effectively Anthropic integrates the team and advances its life sciences strategy.
